Nacuity Pharmaceuticals
CompanyUnited States
Nacuity Pharmaceuticals develops 2 assets, the furthest in phase 3 (NPI-001 in retinitis pigmentosa). Mostly small molecule acting on Oxidative stress and ROS signalling; based in the United States.
- 2
- Assets
- Furthest stage
- Phase 3
- 2
- Trials
- 3
- Signals
Pipeline
2Replenishes intracellular glutathione to reduce oxidative stress and protect retinal photoreceptors.
Phase 3, Small molecule, Oxidative stress and ROS signalling, retinitis pigmentosa, usher syndrome
Provides sustained antioxidant activity in the eye to reduce oxidative damage and delay cataract progression.
Phase 1, Small molecule, Oxidative stress and ROS signalling, cataract
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials2
- Signals4
- Similar companies6